BioSpace News Archive

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced that Gvoke HypoPen™ is now available by prescription in the U.S. for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above.

The first published United States experience of patients who received Abiomed’s newest heart pump, Impella 5.5 with SmartAssist, finds 84% of the patients survived to explant with 76% native heart recovery.

Evelo Biosciences, Inc. announced that clinical data from the Phase 1/2 open-label study of EDP1503, in combination with pembrolizumab, in patients with advanced metastatic microsatellite stable colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors, will be presented at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting being held July 1 - 4, 2020.

XOMA Corporation (NASDAQ: XOMA) announced today Natasha A. Hernday, Senior Vice President, Corporate Development at Seattle Genetics, Inc., has joined the Company’s Board of Directors

Sherlock Biosciences and binx health today announced the companies have entered into a strategic partnership to develop the world’s first rapid, point-of-care diagnostic test for COVID-19 leveraging CRISPR technology. The organi

In response to the growing cell and gene therapy demand in the Philadelphia region, MRA Group (MRA) is pressing onward to deliver by year end, two specialized multi-tenant life science lab buildings: a 65,000+/-SF lab building in the city of Philadelphia and a 72,000+/-SF lab building at Spring House Innovation Park, just outside the city.

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on June 30, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19 Company remains on track to begin clinical trial for COVID-19 vaccine this summer SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for ra

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designations for setmelanotide, an investigational melanocortin-4 receptor (MC4R) agonist, for the treatment of pro-opiomelanocortin (POMC) deficiency obesity and lept

Mpirik, an A.I. healthcare technology company that develops automated patient screening models for cardiovascular disease to drive actionable knowledge, quality and research, has named Dr. Daniel O’Hair as its Chief Medical Officer.